Class summary at a glance.

Every drug in the Bradykinin B2 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $116.7Mcombined across class
Total Rx claims: 5K2K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Icatibant

Brand: Firazyr · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2011-08-25

8 generic mfrs 522 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $116.7M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.